- Home
- EXAS vs IPG Comparison
EXAS vs IPG Comparison
Compare EXAS & IPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXAS
- IPG
- Stock Information
- Founded
- EXAS 1995
- IPG 1902
- Country
- EXAS United States
- IPG United States
- Employees
- EXAS N/A
- IPG N/A
- Industry
- EXAS Medical Specialities
- IPG Advertising
- Sector
- EXAS Health Care
- IPG Consumer Discretionary
- Exchange
- EXAS Nasdaq
- IPG Nasdaq
- Market Cap
- EXAS 10.7B
- IPG 8.9B
- IPO Year
- EXAS N/A
- IPG N/A
- Fundamental
- Price
- EXAS $56.13
- IPG $22.88
- Analyst Decision
- EXAS Strong Buy
- IPG Buy
- Analyst Count
- EXAS 20
- IPG 9
- Target Price
- EXAS $70.68
- IPG $33.22
- AVG Volume (30 Days)
- EXAS 3.3M
- IPG 6.3M
- Earning Date
- EXAS 07-30-2025
- IPG 07-23-2025
- Dividend Yield
- EXAS N/A
- IPG 5.72%
- EPS Growth
- EXAS N/A
- IPG N/A
- EPS
- EXAS N/A
- IPG 1.31
- Revenue
- EXAS $2,828,128,000.00
- IPG $9,001,000,000.00
- Revenue This Year
- EXAS $14.58
- IPG N/A
- Revenue Next Year
- EXAS $12.75
- IPG $2.74
- P/E Ratio
- EXAS N/A
- IPG $17.55
- Revenue Growth
- EXAS 11.57
- IPG N/A
- 52 Week Low
- EXAS $39.97
- IPG $22.51
- 52 Week High
- EXAS $72.83
- IPG $33.05
- Technical
- Relative Strength Index (RSI)
- EXAS 60.75
- IPG 31.68
- Support Level
- EXAS $55.26
- IPG $23.63
- Resistance Level
- EXAS $58.68
- IPG $24.64
- Average True Range (ATR)
- EXAS 1.99
- IPG 0.51
- MACD
- EXAS -0.27
- IPG -0.17
- Stochastic Oscillator
- EXAS 62.66
- IPG 4.09
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
About IPG Interpublic Group of Companies Inc. (The)
Interpublic Group is among the world's largest advertising holding companies based on annual revenue. It provides traditional advertising services along with digital and other services such as public relations through various acquisitions. IPG has made these services available in over 100 countries. The company generates about 65% of revenue in the US and 17% in the UK and Europe. IPG agreed to merge with Omnicom in December 2024, pending regulatory approval.